iRegene Therapeutics, a pioneering biotechnology company based in Chengdu, China, recently announced the successful completion of its Series B+ financing round following the Fast Track Designation (FTD) granted by the U.S. FDA for its flagship product, NouvNeu001. This milestone makes NouvNeu001 the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive such recognition. The Series B+ financing, co-led by prominent venture capital firms and other investors, brings iRegene’s total funding to over USD 40 million, solidifying its position as a leader in the iPSC sector.
The substantial funding secured by iRegene will be pivotal in advancing the global clinical development of NouvNeu001 for Parkinson’s disease and NouvSight001 for retinal degenerative diseases. Additionally, the funds will support the expansion of early-stage research and development efforts, bolster clinical and operational teams, and enhance manufacturing capabilities. This strategic investment underscores the confidence investors have in iRegene’s innovative approach and long-term vision for transforming disease treatment.
NouvNeu001, iRegene’s groundbreaking product, represents a significant advancement in the field of cell therapy. It is the world’s first clinical-stage, iPSC-derived, allogeneic dopaminergic progenitor cell therapy designed specifically for Parkinson’s disease. Having received regulatory clearances in China and the USA to initiate clinical trials, NouvNeu001 is at the forefront of cutting-edge treatments for neurodegenerative disorders. The recent launch of a Phase II clinical trial in China marks a crucial step forward in evaluating the therapy’s efficacy and safety.
Dr. Jun Wei, the Founder and CEO of iRegene Therapeutics, expressed gratitude for the unwavering support of investors and the dedication of the iRegene team in advancing transformative therapies. The company’s mission to reverse disease progression and deliver life-changing treatments to patients globally is now bolstered by the additional funding, which will accelerate clinical programs, expand manufacturing capabilities, and facilitate international expansion. iRegene’s commitment to innovation is evident in its use of “Chemical induction” to reprogram cell fate and enhance cellular functions, setting a new standard in the development of cell therapies.
Since its establishment in 2017, iRegene Therapeutics has been at the forefront of revolutionizing disease treatment by leveraging cutting-edge technologies and a talented team of professionals. By utilizing chemical induction to precisely control cell fate and optimize cellular functions, iRegene has developed a robust pipeline targeting challenging conditions such as Parkinson’s disease and blindness. The company’s proprietary platform enables the generation of human-specific cell types with high purity and enhanced functionality, paving the way for the next generation of chemically derived cell therapies.
Takeaways:
– iRegene Therapeutics’ Series B+ financing and FDA Fast Track Designation for NouvNeu001 highlight the company’s leadership in the field of cell therapies.
– NouvNeu001 is a groundbreaking iPSC-derived cell therapy for Parkinson’s disease, marking a significant advancement in treatment options for neurodegenerative disorders.
– The funding will support iRegene’s global clinical development efforts, manufacturing capabilities, and international expansion, furthering the company’s mission to deliver transformative therapies to patients worldwide.
– By harnessing chemical induction technology, iRegene is pioneering the development of highly specialized and functional cell therapies, offering new hope for patients with currently incurable diseases.
Tags: cell therapies, cell therapy, biotech
Read more on manilatimes.net